Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study-Reference-Cited by-同舟云学术

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study

Published:2022-12 Issue: Volume:66 Page:110-117
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Reinisch Mattea^ORCID,Untch Michael,Mahlberg Rolf,Reimer Toralf^ORCID,Hitschold Thomas,Marmé Frederik,Aydogdu Mustafa,Schmatloch Sabine,Lück Hans-Joachim,Schmidt Marcus^ORCID,Ladda Ekkehart,Sinn Bruno Valentin,Klare Peter,Janni Wolfgang^ORCID,Jackisch Christian,Denkert Carsten,Seiler Sabine^ORCID,Göhler Thomas,Michel Laura,Burchardi Nicole,Stickeler Elmar,Rey Julia^ORCID,Klutinus Nicole,Möbus Volker^ORCID,Loibl Sibylle

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference23 articles.

1. NCCN guidelines version 3.2020 breast cancer;Lurie,2020

2. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †;Cardoso,2019

3. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

4. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

5. HER2-positive breast cancer;Loibl;Lancet,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review;Frontiers in Pharmacology;2024-08-19

2. GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer;npj Breast Cancer;2024-07-30

3. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer;International Journal of Breast Cancer;2024-01